An extremely interesting finding is that the use of SGLT-2 inhibitors in patients suffering from type 2 diabetes (T2DM) is associated with a lower risk of dementia compared to the group of patients taking DPP-4 inhibitors [247]. This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.